Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ORGANIZATION
ORGANIZATION
- Drug Damage Watchdog Challenges Doctors’ View, Says HPV Vaccination Shouldn’t Be Recommended
July 5, 2016
- JMA Vice President Nakagawa Calls for Rules on Use of “Expensive Drugs”
June 27, 2016
- Yokokura Reelected for Third Term as JMA President
June 27, 2016
- NPO Asks MHLW to Take Steps to Ensure Proper Use of Xeplion
June 23, 2016
- PMDA Chief Brings Together Drug Makers, Tech Vendors to Compile Proposal on Digital Health
June 17, 2016
- Re-Pricing Rules Need Drastic Overhaul, Possible Abolishment Should Be Discussed for Z2: FPMAJ
June 14, 2016
- FPMAJ Report Warns of Repercussions from Sovaldi Price Slash
June 14, 2016
- Reimbursement Prices Kept Unchanged for Over 20% of Drugs: FPMAJ Survey
June 13, 2016
- FPMAJ Wants to Avoid Narrowing-Down of Premium-Eligible Products: Kamoya
June 13, 2016
- FPMAJ Drug Pricing Affairs Chief Lashes Out at Proposed Out-of-Cycle Re-Pricing
June 13, 2016
- 9 Pharma-Related Companies to Join to Global Health Innovative Technology Fund
June 8, 2016
- Japan Is at Crossroads, Must Carry On Its Pro-Innovation Policies: PhRMA Chairman
June 3, 2016
- PhRMA Still “Concerned” about Anti-Innovation Policies despite Tax Decision: Japan Chief
June 2, 2016
- Biosimilar Policies Shouldn’t Threaten Biologics Development: EFPIA Japan
May 31, 2016
- Astellas’s Hatanaka Elected as New JPMA President
May 27, 2016
- Sumitomo Dainippon Pres. Tada Picked as New Chief of FPMAJ
May 27, 2016
- No Need to Add Hep B Vaccines to Public Immunization Program: Drug Damage Watchdog
May 13, 2016
- Citizen’s Group Says Kaketsuken Shouldn’t Profit from Suspension-Cleared Products, Surcharges Needed
May 13, 2016
- EFPIA Takes to Nagata-cho to Call for Real Dialogue
April 28, 2016
- National Univ. Hospital Council to Disclose Funding with Companies’ Names Not Affiliated with JPMA
April 27, 2016
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…